Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

16.110
+1.67011.57%
Volume:4.18M
Turnover:65.99M
Market Cap:17.09B
PE:-53.62
High:16.340
Open:14.500
Low:14.460
Close:14.440
52wk High:18.750
52wk Low:4.090
Shares:1.06B
HK Float Shares:1.06B
Volume Ratio:6.58
T/O Rate:0.39%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.300
ROE:-12.77%
ROA:-12.32%
PB:8.08
PE(LYR):-53.62
PS:6384.49

Loading ...

Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered Glp-1R/Gipr/Gcgr Triple Peptide Agonist, Asc37, for Clinical Development

THOMSON REUTERS
·
Jan 20

HK Stock Movement | Ascletis Pharma-B (01672) Surges Over 5% Before Noon, ASC30 Shows Significant Competitive Edge, Institutions Highlight High BD Potential

Stock News
·
Jan 20

Why Ascletis Pharma (SEHK:1672) Is Up 6.3% After FDA Clears ASC30 Diabetes Trial And Obesity Data

Simply Wall St.
·
Jan 16

Hong Kong Stock Anomaly | Ascletis Pharma-B (01672) Surges Over 6% in Afternoon Trading on Strong ASC30 Data, Company Raises Buyback Cap to HK$500 Million

Stock News
·
Jan 14

Ascletis Pharma (SEHK:1672) Is Up 9.9% After FDA Clears ASC30 Phase II Diabetes Trial - What's Changed

Simply Wall St.
·
Jan 09

Hong Kong Stocks Close Mixed; Ascletis Pharma Receives U.S. Nod to Begin Phase II Trial of ASC30

MT Newswires Live
·
Jan 05

BRIEF-Ascletis Pharma Receives FDA IND Clearance For ASC30 Phase II Study

Reuters
·
Jan 05

ASCLETIS-B (01672) Announces FDA Approval of IND for 13-Week Phase II Study of ASC30 in Diabetic Subjects

Stock News
·
Jan 05

Ascletis Pharma Inc - Receives FDA Ind Clearance for Asc30 Phase Ii Study

THOMSON REUTERS
·
Jan 05

Ascletis Pharma Wins FDA IND Clearance for Phase II Diabetes Study

Reuters
·
Jan 05

Zhixiang Hong Kong Stock Repurchase Statistics | January 1

Stock News
·
Jan 01

Ascletis-B (01672) Repurchases 200,000 Shares for HK$2.4829 Million on December 29

Stock News
·
Dec 29, 2025

Ascletis Pharma Repurchases 200,000 Shares for HK$2.48 Million in HKEX Filing

Reuters
·
Dec 29, 2025

Orient Securities Initiates Coverage on Ascletis Pharma-B (01672) with "Buy" Rating, Sets Target Price at HK$18.38

Stock News
·
Dec 29, 2025

Ascletis Pharma Files HKEX Disclosure on Repurchase of 100,000 Shares at HKD 1,254,850

Reuters
·
Dec 24, 2025

HK Stock Buyback Summary | Dec 24

Stock News
·
Dec 24, 2025

ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$2.49 Million on December 22

Stock News
·
Dec 22, 2025

Ascletis Pharma Repurchases 200,000 Shares for HKD 2.56 Million in HKEX Filing

Reuters
·
Dec 19, 2025

Do Ascletis Pharma’s (SEHK:1672) ASC50 Phase I Results Hint At A Scalable Autoimmune Strategy?

Simply Wall St.
·
Dec 19, 2025

HK Stock Buyback Summary | December 18

Stock News
·
Dec 18, 2025